The clinical impact of ICOS signal in colorectal cancer patients.
Open Access
- 18 February 2016
- journal article
- research article
- Published by Taylor & Francis Ltd in OncoImmunology
- Vol. 5 (5), e1141857
- https://doi.org/10.1080/2162402X.2016.1141857
Abstract
The inducible T-cell co-stimulator (ICOS) belongs to the B7-CD28 immunoglobulin superfamily, which is currently the subject of intense study due to great successes gained in treatment of different malignancies by disrupting their family members. However, the role of ICOS played in colorectal cancer (CRC) remains poorly understood. A tissue microarray (n = 310) was stained with the ICOS specific antibody and ICOS expression is decreased in patients with either lymphatic or distant metastasis and inversely associated with CEA level and TNM stage of CRC patients. Importantly, high ICOS expression is significantly correlated with overall survival (OS) of CRC patients (n = 230, p < 0.001), and ICOS expression is also proved to be an independent prognostic factor by multivariate analysis. Surgical excised CRC specimens (n = 26) were enzymatically digested to get the tumor-infiltrating leukocytes and ICOS is mainly expressed on CD4+ T cells and its ligand ICOSL is detected on macrophages and tumor cells. ICOS expression level is associated with increased cytotoxic T lymphocyte antigen (CTLA)-4 (p < 0.001) and programmed death (PD-1) (p = 0.005) expression on T cells and more infiltrated CD8+ T cells (p < 0.001). Interestingly, ICOS+CD4+ cells isolated from tumor tissues have high T-bet and interferon (IFN)γ expression, the characteristics of Th1 cells, compared to ICOS−CD4+ cells. In addition, the correlation between the percentage of ICOS+CD4+ T cells in tumor tissue and peripheral blood was detected. Conclusively, expression of ICOS is associated with improved survival in CRC and percentage of ICOS+CD4+ cells acting as Th1 cells in either primary tumor tissue or peripheral blood may be a clinical biomarker for good prognosis of CRC patients.Keywords
This publication has 23 references indexed in Scilit:
- B7 family checkpoint regulators in immune regulation and diseaseTrends in Immunology, 2013
- Clinical impact of programmed cell death ligand 1 expression in colorectal cancerEuropean Journal Of Cancer, 2013
- ICOS is associated with poor prognosis in breast cancer as it promotes the amplification of immunosuppressive CD4+T cells by plasmacytoid dendritic cellsOncoImmunology, 2013
- ICOS-Ligand Expression on Plasmacytoid Dendritic Cells Supports Breast Cancer Progression by Promoting the Accumulation of Immunosuppressive CD4+ T CellsCancer Research, 2012
- B7-H2 Is a Costimulatory Ligand for CD28 in HumanImmunity, 2011
- Immunology and immunotherapy of colorectal cancerCritical Reviews in Oncology/Hematology, 2003
- The B7–CD28 superfamilyNature Reviews Immunology, 2002
- The CD28-Related Molecule ICOS Is Required for Effective T Cell–Dependent Immune ResponsesImmunity, 2000
- B7h, a Novel Costimulatory Homolog of B7.1 and B7.2, Is Induced by TNFαImmunity, 1999
- ICOS is an inducible T-cell co-stimulator structurally and functionally related to CD28Nature, 1999